Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with respect to the Improvement of quality of life: DLQI and SF-36 Results of the PRIME Study

Augustin M, Thaci D, Reich K, Mrowietz U, Kneidl J, Hentschke C, Simang M, Sieder C, Melzer N, Sticherling M (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

Book Volume: 15

Pages Range: 144-145

Authors with CRIS profile

Michael Sticherling Professur für Dermatologie

Involved external institutions

Novartis AG CH Switzerland (CH) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Dermatologikum Hamburg DE Germany (DE)

How to cite

APA:

Augustin, M., Thaci, D., Reich, K., Mrowietz, U., Kneidl, J., Hentschke, C.,... Sticherling, M. (2017). Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with respect to the Improvement of quality of life: DLQI and SF-36 Results of the PRIME Study. (pp. 144-145).

MLA:

Augustin, M., et al. "Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with respect to the Improvement of quality of life: DLQI and SF-36 Results of the PRIME Study." 2017. 144-145.

BibTeX: Download